Grifols (Grifols) Investments And Advances : $616 Mil (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Grifols Investments And Advances?

Grifols's Investments And Advances for the quarter that ended in Dec. 2023 was $616 Mil.

Grifols's quarterly Investments And Advances increased from Jun. 2023 ($2,748 Mil) to Sep. 2023 ($2,772 Mil) but then declined from Sep. 2023 ($2,772 Mil) to Dec. 2023 ($616 Mil).

Grifols's annual Investments And Advances increased from Dec. 2021 ($2,557 Mil) to Dec. 2022 ($2,574 Mil) but then declined from Dec. 2022 ($2,574 Mil) to Dec. 2023 ($616 Mil).

Grifols Investments And Advances Historical Data

The historical data trend for Grifols's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Investments And Advances Chart

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Investments And Advances

Get a 7-Day Free Trial

159.98

2,408.83

2,557.18

2,574.07

616.25

Grifols Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Investments And Advances	Get a 7-Day Free Trial															-	2,574.07	2,747.61	2,771.93	616.25

Grifols Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (OTCPK:GIKLY) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

GIFOF:USA GIFLF:USA GRFS:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain OZTA:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.